- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06795438
Effects of Green Tea on Cardiometabolic Outcomes
March 24, 2025 updated by: Jonathan Sinclair, University of Central Lancashire
Effects of Green Tea Supplementation on Cardiometabolic Parameters
Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount.
Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs.
It has been postulated that Green tea may be beneficial in improving cardiometabolic outcomes.
However, to date, no research has explored this using a placebo randomized intervention.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jonathan Sinclair, PhD, DSc
- Phone Number: 07875651533
- Email: jksinclair@uclan.ac.uk
Study Locations
-
-
Lancashire
-
Preston, Lancashire, United Kingdom, PR4 0PE
- University of Central Lancashire
-
Contact:
- Jonathan Sinclair, DSc, PhD
- Phone Number: 07875651533
- Email: jksinclair@uclan.ac.uk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy
- Between 18 & 65 years
- Non-smoker
- BMI < 30
- Able to give informed consent
Exclusion Criteria:
- Pregnancy
- Diabetes or any other metabolic/ uncontrolled hypertensive conditions
- Food allergies to quercetin
- Habitual consumption of quercetin
- Not regularly taking medication or antioxidant supplements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Green tea
Green tea tablets 1000mg 1 x per day
|
Green tea tablets 1000mg 1 x per day
|
|
Placebo Comparator: Placebo
Placebo control 1 x blinded placebo tablet per day
|
Placebo control 1 x blinded placebo tablet per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Systolic blood pressure
Time Frame: Baseline
|
Systolic blood pressure - measured using a digital blood pressure monitor
|
Baseline
|
|
Systolic blood pressure
Time Frame: 20 days
|
Systolic blood pressure - measured using a digital blood pressure monitor
|
20 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent bodyfat
Time Frame: Baseline
|
Participants percentage composition of fat - measured using bio-electrical impedance
|
Baseline
|
|
Percent bodyfat
Time Frame: 20 days
|
Participants percentage composition of fat - measured using bio-electrical impedance
|
20 days
|
|
Waist to hip ratio
Time Frame: Baseline
|
Ratio of waist to hip circumference - measured using anthropocentric tape
|
Baseline
|
|
Waist to hip ratio
Time Frame: 20 days
|
Ratio of waist to hip circumference - measured using anthropocentric tape
|
20 days
|
|
Blood glucose
Time Frame: Baseline
|
Capillary blood glucose - mmol/L
|
Baseline
|
|
Blood glucose
Time Frame: 20 days
|
Capillary blood glucose - mmol/L
|
20 days
|
|
Blood triglycerides
Time Frame: Baseline
|
Capillary blood triglycerides - mmol/L
|
Baseline
|
|
Blood triglycerides
Time Frame: 20 days
|
Capillary blood triglycerides - mmol/L
|
20 days
|
|
Blood cholesterol (Total, HDL & LDL)
Time Frame: Baseline
|
Capillary blood cholesterol - mmol/L
|
Baseline
|
|
Blood cholesterol (Total, HDL & LDL)
Time Frame: 20 days
|
Capillary blood cholesterol - mmol/L
|
20 days
|
|
State Trait Anxiety Inventory
Time Frame: Baseline
|
Psychological wellbeing - the state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.
|
Baseline
|
|
State Trait Anxiety Inventory
Time Frame: 20 days
|
Psychological wellbeing - the state trait anxiety inventory is a 40 item questionnaire with each question having a 1-4 score system, thus the maximum score is 80 which indicates the highest level of anxiety.
|
20 days
|
|
Insomnia Severity Index
Time Frame: Baseline
|
Sleep quality - The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia.
The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.
|
Baseline
|
|
Insomnia Severity Index
Time Frame: 20 days
|
Sleep quality - The Insomnia Severity Index is a brief instrument designed to assess the severity of both nighttime and daytime components of insomnia.
The Insomnia Severity Index is a 7-item self-report questionnaire yielding a total score ranging from 0 to 28.
|
20 days
|
|
Pittsburgh Sleep Quality Index
Time Frame: Baseline
|
Sleep quality - The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components.
Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.
|
Baseline
|
|
Pittsburgh Sleep Quality Index
Time Frame: 20 days
|
Sleep quality - The Pittsburgh Sleep Quality index, is a questionnaire that consists of 19 self-rated questions, grouped into 7 components.
Each component is scored separately, weighted equally on a 0 - 3 scale and the scores of the 7 components are then added to give a global score, which has a range of 0 - 21 with higher scores indicating worse sleep quality.
|
20 days
|
|
Epworth Sleepiness Scale
Time Frame: Baseline
|
Sleep quality - The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions.
Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.
|
Baseline
|
|
Epworth Sleepiness Scale
Time Frame: 20 days
|
Sleep quality - The Epworth Sleepiness Scale is a self-administered questionnaire with 8 questions.
Respondents are asked to rate, on a 4-point scale (0-3) with a maximum score of 24.
|
20 days
|
|
Triglyceride glucose index
Time Frame: Baseline
|
Calculated as the natural logarithm of (blood triglycerides x blood glucose) /2)
|
Baseline
|
|
Triglyceride glucose index
Time Frame: 20 days
|
Calculated as the natural logarithm of (blood triglycerides x blood glucose) /2)
|
20 days
|
|
Diastolic blood pressure
Time Frame: Baseline
|
Diastolic blood pressure - measured using a digital blood pressure monitor
|
Baseline
|
|
Diastolic blood pressure
Time Frame: 20 days
|
Diastolic blood pressure - measured using a digital blood pressure monitor
|
20 days
|
|
Coop-Wonka chart
Time Frame: Baseline
|
Psychological wellbeing - The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring
|
Baseline
|
|
Coop-Wonka chart
Time Frame: 20 days
|
Psychological wellbeing - The Coop-Wonka chart is a six item questionnaire with a 1-5 scoring
|
20 days
|
|
Beck Depression Inventory
Time Frame: Baseline
|
sychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.
|
Baseline
|
|
Beck Depression Inventory
Time Frame: 20 days
|
sychological wellbeing - the Beck Depression Inventory is a 21 questionnaire with questions that range in scoring from 0-3, thus the maximum score is 63 which is the highest depression score possible.
|
20 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2025
Primary Completion (Estimated)
February 1, 2027
Study Completion (Estimated)
June 1, 2027
Study Registration Dates
First Submitted
January 21, 2025
First Submitted That Met QC Criteria
January 21, 2025
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 27, 2025
Last Update Submitted That Met QC Criteria
March 24, 2025
Last Verified
March 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Green tea cardiometabolic
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiometabolic Syndrome
-
University of Central LancashireDoNotAge.orgNot yet recruitingCardiometabolic Syndrome
-
Global Centre for Asian Women's HealthYong Loo Lin School of MedicineRecruitingWomen Health | Cardiometabolic Risk Factors | Cardiometabolic ConditionsSingapore
-
University of Alabama, TuscaloosaMcCormick Science InstituteRecruitingCardiometabolic SyndromeUnited States
-
Universiti Putra MalaysiaNot yet recruitingCardiometabolic SyndromeMalaysia
-
University of Central LancashireDoNotAge.orgRecruiting
-
National University Hospital, SingaporeRecruitingThe Platform for Interdisciplinary Cardiovascular-metabolic-neurovascular Diseases (PICMAN) (PICMAN)Cardiometabolic SyndromeSingapore
-
Universidad Francisco de VitoriaCompletedCardiometabolic SyndromeSpain
-
Jonathan SinclairCompleted
-
University of BrawijayaPT. Sahabat Lingkungan HidupEnrolling by invitation
-
Arkansas Children's Hospital Research InstituteEnrolling by invitationCardiometabolic HealthUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States